Terms: = Kidney tumors AND RUNX1, PEBP2A2, 861, ENSG00000159216, Q01196, AML1, CBFA2, AMLCR1 AND Treatment
23 results:
1. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian Cancer.
Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
[TBL] [Abstract] [Full Text] [Related]
2. MTAN: A semi-supervised learning model for kidney tumor segmentation.
Sun P; Yang S; Guan H; Mo T; Yu B; Chen Z
J Xray Sci Technol; 2023; 31(6):1295-1313. PubMed ID: 37718833
[TBL] [Abstract] [Full Text] [Related]
3. Integrating On-treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma.
Saal J; Bald T; Eckstein M; Ralser DJ; Ritter M; Brossart P; Grünwald V; Hölzel M; Ellinger J; Klümper N
JAMA Oncol; 2023 Aug; 9(8):1048-1055. PubMed ID: 37347489
[TBL] [Abstract] [Full Text] [Related]
4. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
Bedke J; Rini BI; Plimack ER; Stus V; Gafanov R; Waddell T; Nosov D; Pouliot F; Soulières D; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Tamada S; Nguyen AM; Wan S; Perini RF; Rhoda Molife L; Atkins MB; Powles T
Eur Urol; 2022 Oct; 82(4):427-439. PubMed ID: 35843776
[TBL] [Abstract] [Full Text] [Related]
5. Young age is associated with decreased recurrence for renal cell carcinoma.
Liu F; Davaro F; Wong R; Siddiqui S; Hamilton Z
Can J Urol; 2022 Jun; 29(3):11142-11149. PubMed ID: 35691035
[TBL] [Abstract] [Full Text] [Related]
6. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer treatment.
Wallach JD; Deng Y; McCoy RG; Dhruva SS; Herrin J; Berkowitz A; Polley EC; Quinto K; Gandotra C; Crown W; Noseworthy P; Yao X; Shah ND; Ross JS; Lyon TD
JAMA Netw Open; 2021 Oct; 4(10):e2130587. PubMed ID: 34677594
[TBL] [Abstract] [Full Text] [Related]
7. Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
Zhou X; Fu G; Zu X; Xu Z; Li HT; D'souza A; Tulpule V; Quinn DI; Bhowmick NA; Weisenberger DJ; Liang G; Chen J
Urol Oncol; 2022 Jan; 40(1):12.e13-12.e22. PubMed ID: 34454823
[TBL] [Abstract] [Full Text] [Related]
8. Small single perivascular hepatocellular carcinoma: comparisons of radiofrequency ablation and microwave ablation by using propensity score analysis.
An C; Li WZ; Huang ZM; Yu XL; Han YZ; Liu FY; Wu SS; Yu J; Liang P; Huang J
Eur Radiol; 2021 Jul; 31(7):4764-4773. PubMed ID: 33399908
[TBL] [Abstract] [Full Text] [Related]
9. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract] [Full Text] [Related]
10. Targeted therapy for metastatic renal cell carcinoma.
Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
[TBL] [Abstract] [Full Text] [Related]
11. The effect of a treatment delay on outcome in metastatic renal cell carcinoma.
Iacovelli R; Galli L; De Giorgi U; Porta C; Nolè F; Zucali P; Sabbatini R; Mosca A; Atzori F; Santini D; Facchini G; Fornarini G; Buti S; Massari F; Masini C; Ricotta R; Biasco E; Lolli C; Gri N; Verri E; Miggiano C; Vitale MG; Tortora G
Urol Oncol; 2019 Aug; 37(8):529.e1-529.e7. PubMed ID: 30935843
[TBL] [Abstract] [Full Text] [Related]
12. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study.
Wei JH; Feng ZH; Cao Y; Zhao HW; Chen ZH; Liao B; Wang Q; Han H; Zhang J; Xu YZ; Li B; Wu JT; Qu GM; Wang GP; Liu C; Xue W; Liu Q; Lu J; Li CX; Li PX; Zhang ZL; Yao HH; Pan YH; Chen WF; Xie D; Shi L; Gao ZL; Huang YR; Zhou FJ; Wang SG; Liu ZP; Chen W; Luo JH
Lancet Oncol; 2019 Apr; 20(4):591-600. PubMed ID: 30880070
[TBL] [Abstract] [Full Text] [Related]
13. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
[TBL] [Abstract] [Full Text] [Related]
14. Comparison of perioperative, renal and oncologic outcomes in robotic-assisted versus open partial nephrectomy.
Tan JL; Frydenberg M; Grummet J; Hanegbi U; Snow R; Mann S; Begashaw K; Moon D
ANZ J Surg; 2018 Mar; 88(3):E194-E199. PubMed ID: 28922687
[TBL] [Abstract] [Full Text] [Related]
15. Initial computed tomography imaging details during first-line systemic therapy is of significant prognostic value in patients with naïve, unresectable metastatic renal cell carcinoma.
Kim SH; Park WS; Kim SH; Seo HK; Joung JY; Lee KH; Chung J
PLoS One; 2017; 12(5):e0177975. PubMed ID: 28562690
[TBL] [Abstract] [Full Text] [Related]
16. Patient Function and the Value of Surgical Care for kidney Cancer.
Tan HJ; Shirk JD; Chamie K; Litwin MS; Hu JC
J Urol; 2017 May; 197(5):1200-1207. PubMed ID: 27986531
[TBL] [Abstract] [Full Text] [Related]
17. Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients.
Roseweir AK; Qayyum T; Lim Z; Hammond R; MacDonald AI; Fraser S; Oades GM; Aitchison M; Jones RJ; Edwards J
BMC Cancer; 2016 Mar; 16():229. PubMed ID: 26984511
[TBL] [Abstract] [Full Text] [Related]
18. Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer.
Di Lorenzo G; Bracarda S; Gasparro D; Gernone A; Messina C; Zagonel V; Puglia L; Bosso D; Dondi D; Sonpavde G; Lucarelli G; De Placido S; Buonerba C
Medicine (Baltimore); 2016 Jan; 95(2):e2299. PubMed ID: 26765406
[TBL] [Abstract] [Full Text] [Related]
19. Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway.
Čokić VP; Mossuz P; Han J; Socoro N; Beleslin-Čokić BB; Mitrović O; Subotički T; Diklić M; Leković D; Gotić M; Puri RK; Noguchi CT; Schechter AN
PLoS One; 2015; 10(8):e0135463. PubMed ID: 26275051
[TBL] [Abstract] [Full Text] [Related]
20. Co-occurrence of second primary malignancy in patients with thyroid cancer.
Hsu CH; Huang CL; Hsu YH; Iqbal U; Nguyen PA; Jian WS
QJM; 2014 Aug; 107(8):643-8. PubMed ID: 24623860
[TBL] [Abstract] [Full Text] [Related]
[Next]
